A Guidelines Office, consisting of a board and, currently, 19 panels and 2 ad-hoc panels (involving nearly 160 clinicians) have been tasked with the production of clinical urological guidelines.
All working panels have an international representation to ensure a balanced and representative view. A significant proportion of all clinical experts involved in EAU guidelines activities are non-urologists who contribute expertise from other specialties and disciplines of relevance to the EAU clinical guidelines.
All guidelines panel members are compelled to complete a potential Conflict of Interest form as well as sign a Confidentiality agreement. Disclosures can be consulted online.
Additional information on these policies can be found on this page.
Participation in a Guidelines panel involves a significant commitment and investment of time. The EAU and its membership are most grateful for their contributions and commitment to the EAU guidelines effort.
Guidelines Office Board
| Chairman | K.F. Parsons | Liverpool (GB) | Conflict of Interest |
|
| Vice-Chairman | J. Irani | Poitiers (FR) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Company speaker honorarium | Astellas | Sanofi-Pasteur | Ferring | | Ipsen | | | | Trial participation | Astellas | GenProbe | Ferring | | | | | | Research grants | Astellas | | | | | | |
|
| Member | C. Llorente Abarca | Madrid (ES) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Company consultant | Astellas | Recordati | | | | | | | Company speaker honorarium | GSK | AMS | | | | | | | Trial participation | Recordati | | | | | | |
|
| Member | C. R. Chapple | Sheffield (UK) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Company consultant | Astellas | Pfizer | Xention | | Allergan | Recordati | Ono | | Company speaker honorarium | Astellas | Pfizer | Ranbaxy | | | | | | Trial participation | Astellas | Pfizer | Allergan | | Recordati | Tanabe | | | Research grants | Allergan | Pfizer | | | | | | | Other – please indicate | | Company | Conflict Type |
| Novartis |
Consultant |
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
| Member | J. N`Dow | Abberdeen (Scotland, UK) | Conflict of Interest |
|
| Member | M. Fall | Gothenburg (SE) | Pending |
|
| Member | R. Sylvester | Brussels (BE) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Company consultant | Bioniche | Allergan | Astrazeneca | | | | | | Company speaker honorarium | Kyowa 2008 EAU Satellite Symposium | | | | | | |
|
| Member | T. Hanuš | Prague (CZ) | Conflict of Interest |
|
| Member | T. Loch | Flensburg (DE) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Equity interests | Fresenius-Kabi | | | | | | | | Company consultant | Fresenius-Kabi | Theranostik | | | | | | | Company speaker honorarium | Takeda | | | | | | |
|
Members EAU Guidelines Office Panels
Select a panel:| Chairman | P. Albers | Kassel (DE) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Royalties | Thieme Books | | | | | | | | Company consultant | Pfizer | MSD | Novartis | | | | | | Company speaker honorarium | Pfizer | Novartis | Sanofi-Aventis | | Amgen | AstraZeneca | Astellas | | Trial participation | Novacea | Sanofi-Aventis | Bayer | | Astra Zeneca | Novartis | Ferring | | Research grants | Novartis Oncology | Bayer Oncology | | | | | |
|
| Member | W. Albrecht | Mistelbach (AT) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Company speaker honorarium | Takeda | Astellas | Aesca | | | | |
|
| Member | F. Algaba | Barcelona (ES) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Company speaker honorarium | INIBSA | | | | | | | | Trial participation | PFISER | | | | | | |
|
| Member | C. Bokemeyer | Hamburg (DE) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Company consultant | Fresenius Biotech | Sanofi Aventis | Ortho Biotech | | MSD | | | | Company speaker honorarium | Roche | Sanofi Aventis | Amgen | | MSD | Fresenius Biotech | Chugai | | Trial participation | several over years | | | | | | | | Research grants | Bristol | Lilly | Fresenius | | Merck Serono | Sanofi Aventis | |
|
| Member | G. Cohn-Cedermark | Stockholm (SE) | Conflict of Interest |
|
| Member | K. Fizazi | Vellejuif/Paris (FR) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Company consultant | Novartis, Amgen, Sanofi-Aventis, Astrazeneca, Ipsen, Janssen, Millennium, Keocyt, Astellas | | | | | | | | Company speaker honorarium | Amgen, Janssen, Sanofi-Aventis, Novartis | | | | | | | | Trial participation | Amgen, Sanofi-Aventis, Astrazeneca, Janssen, Medivation, Millenium, Celgene, Oncogenex, BMS | | | | | | |
|
| Member | A. Horwich | London (UK) | Conflict of Interest |
|
| Member | M.P. Laguna | Amsterdam (NL) | Conflict of Interest |
| Company Name | Company Name | Company Name | | Other – please indicate | | Company | Conflict Type |
| EAU |
Guidelines panel member |
| |
|
| |
|
| |
|
| |
|
| |
|
|
|